A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

NCT05574010 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

128

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Celiac Disease

Interventions

DRUG: Cohort 1 in Part A
DRUG: Cohort 2 in Part A
OTHER: Placebo: Group 1 in Part B and Part C
DRUG: Group 2 in Part B and Part C
DRUG: Group 3 in Part B and Part C
DRUG: Group 4 in Part B and Part C

Sponsor

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

Collaborators

[object Object]